Biochemical Auto-Diagnostics Market Assessment, By Component [Instruments, Reagents, Consumables], By Instrument Type [Fully Automatic Biochemistry Analyzers, Semi-Automatic Biochemistry Analyzers], By Application [Clinical Diagnostics, Bioreactor Byprodu

Biochemical Auto-Diagnostics Market Assessment, By Component [Instruments, Reagents, Consumables], By Instrument Type [Fully Automatic Biochemistry Analyzers, Semi-Automatic Biochemistry Analyzers], By Application [Clinical Diagnostics, Bioreactor Byproduct Detection, Drug Development Applications, Others], By End-user[ Hospitals, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations], By Region, Opportunities and Forecast, 2017-2031F

Global biochemical auto-diagnostics market is projected to witness a CAGR of 5.7% during the forecast period 2024-2031, growing from USD 5.01 billion in 2023 to USD 7.81 billion in 2031. The growing demand for rapid and accurate diagnostic tests primarily drives the biochemical auto-diagnostics market. Automation of laboratory procedures, emphasis on early diagnosis of diseases, and advancements in technologies used for biochemistry diagnostics are acting as other growth-inducing factors. The rapidly growing disease burden of chronic and infectious diseases significantly raises the demand for automated diagnostics procedures, further expanding the scope of this market. The growing geriatric population, which is most prone to catching diseases, increases the demand for diagnostics. Regulatory support from concerned authorities for technology expansion in diagnostics further boosts the market growth.

However, the high cost of purchasing and operating the automated biochemistry analyzer raises affordability issues for laboratories, which is one of the major challenges for the manufacturers. A significant challenge also comes from resistance to adopting new technology and a lack of suitable training modules, although companies are working on this now.

In June 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray) launched the high-throughput M1000 Chemistry and Immunoassay Integrated Solution. The solution includes the BS-2800M Chemistry Analyzer, CL-8000i Chemiluminescence Immunoassay Analyzer, and an intelligent sample delivery module.

Growing Demand for Rapid and Accurate Diagnostic Tests

The growing demand for rapid and accurate diagnostic tests is driven by factors such as the rising prevalence of noncommunicable diseases, an aging population, and the need for immediate medical diagnosis, screening, and surveillance. The demand for diagnostic testing continues to rise due to the increasing prevalence of chronic conditions and the aging population. As the need for immediate medical diagnosis and surveillance increases, the demand for advanced analyzers and innovative technologies rises. This has led to technological innovations in clinical chemistry analyzers, enabling early disease detection and testing on a larger scale. The growing demand for diagnostics can be easily catered to through auto-diagnostics biochemistry analyzers and consumables, further expanding the market. Manufacturers are actively involved in producing solutions for rapid and precise biochemistry analyzers.

For instance, in May 2023, Beckman Coulter unveiled the DxI 9000 Access Immunoassay Analyzer. The DxI 9000 Analyzer can perform up to 215 tests per hour per square meter, making it the most productive immunoassay analyzer in terms of footprint. Beckman Coulter is a leading provider of advanced diagnostics solutions across the globe.

Rapid Automation of Laboratory Procedures

The rapid automation of laboratory procedures has increased the demand for automated biochemistry analyzers. As diagnostic laboratories become more automated, sophisticated instruments can complete hundreds to thousands of tests. This has led to an increased demand for automated analyzers. Automation allows for fast, cost-efficient, and high-quality testing, essential to meet the growing sample load and the need for operational excellence in clinical laboratories. Additionally, automation has been an integral part of most clinical chemistry workflows for decades, allowing labs to handle many test requests and reduce costs.

In July 2023, Siemens Healthineers launched a US-FDA-approved Atellica CI Analyser for immunoassay diagnostics. The Atellica CI Analyzer allows standalone and satellite labs to access the same reagents, consumables, and intelligent software as Atellica Solution. This technology has been designed to fit into a small 1.9m² space, perfect for laboratories with limited space. It allows labs to provide more reliable and timely results by allowing random access sampling, micro-volume aspiration, and automatic scheduling of maintenance and quality control.

Dominance of Fully Automatic Biochemistry Analyzers Segment

Fully automatic biochemistry analyzers are preferred over semi-automatic ones for several reasons. One of the primary advantages is that fully automatic analyzers require little or no manual intervention, reducing the potential for human error. They can also handle a higher throughput of samples, making them more suitable for larger laboratories with high testing volumes. Additionally, fully automatic analyzers offer more automation, from sample addition to result reporting, leading to improved efficiency and streamlined testing processes. Furthermore, the test results of fully automatic analyzers are generally more accurate and convenient than semi-automatic analyzers. Fully automatic analyzers are ideal for high sample volumes and efficient processing, semi-automatic analyzers may be sufficient for smaller laboratories or point-of-care settings with lower sample volumes and can accommodate a slightly longer turnaround time.

In July 2023, Anbio launched a fully automated CLIA analyzer. The Anbio ADL i1910 is an affordable and compact chemiluminescence immunoassay analyzer that provides a comprehensive range of testing options for analytes in human serum, plasma, whole blood, and urine samples. It uses the direct chemiluminescence method to ensure accurate and reliable hormone detection, disease screening, and antigen analysis results.

Hospitals to Lead the End-user Segment

Hospitals use biochemical analyzers for various purposes, including routine check-ups, disease screening, confirmation tests, and diagnosis of different ailments. These analyzers are critical for assessing chemicals in biological samples, analyzing analytes such as proteins, electrolytes, enzymes, and metabolites, and evaluating the performance of organs like the liver, heart, and kidneys. They are also helpful in drug monitoring, detecting drug misuse, and diagnosing infectious diseases. The growing demand for diagnostic testing has led to an increase in the usage of biochemical analyzers, making hospitals one of the primary consumers of these devices. Market players are designing products to cater to the specific requirements of hospitals.

In May 2023, Wondfo launched the Ucare-6000 Automatic Blood Gas Biochemical Analyzer at the 20th China Association of Clinical Laboratory Practice Expo (CACLP). The Ucare-6000 automatic blood gas biochemical analyzer offers accuracy, efficiency, flexibility, and simplified operation. It uses electrochemistry sensing technology, microfluidic technology, and thin-film microelectrode technology. With its sound QC system, it can perform automatic calibration and internal QC to ensure accurate results.

North America to be the Dominating Region

North America is the leading consumer of biochemistry analyzers due to the rising prevalence of chronic diseases, such as diabetes and cardiovascular disorders, which require efficient diagnostic tools to manage and monitor these conditions. The need for rapid and on-site diagnostic solutions is also driving the demand for biochemistry analyzers, and the trend toward miniaturization is contributing to cost-effectiveness. The United States is a significant market for biochemistry analyzers, with high investments in research and development initiatives. The presence of key market players like Beckman Coulter Inc., and Abbott Diagnostics Inc. in the region also contributed to the region's dominance in this market.

Future Market Scenario (2024 – 2031F)

The major drivers of the market include digital transformation for labs, increasing research and development activities across the healthcare industry, and growing expenditure on the diagnostics industry.

The growing affinity of healthcare providers for adopting technology-based solutions for diagnostics is anticipated to increase the demand for the biochemical auto-diagnostics market.

Fully automated biochemical analyzers are preferred over semi-automated biochemical analyzers due to enhanced efficacy and efficiency and are expected to be the dominating segment throughout the assessment period.

Hospitals are anticipated to be the leading end-users for this market due to the growing requirement for rapid diagnostic tests, owing to the high disease burden and growing geriatric population.

Key Players Landscape and Outlook

The key players in the landscape of the biochemical auto-diagnostics market include companies involved in the manufacturing and distribution of biochemistry analyzers and biochemical diagnostic instruments. Some prominent companies in this market are Roche Diagnostics GmbH, Siemens AG, Beckman Coulter Inc., and Abbott Diagnostics. These companies are known for their advanced healthcare technologies and have a significant market presence. The market is expected to witness healthy competition with the integration of new technologies.

In December 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. announced the acquisition of a 75% stake in Germany-based DiaSys Diagnostic Systems GmbH, this acquisition makes DiaSys, a subsidiary of Mindray. The acquisition will expand the IVD offerings of Mindray including the biochemical analyzers.